Last updated: October 28, 2026
Dofetilide is a mature, low-volume generic antiarrhythmic used to maintain normal sinus rhythm in patients with atrial fibrillation or atrial flutter. The product is commercially established but financially limited by generic competition, low dosing strength, mandatory inpatient initiation, and a narrow prescriber base. Tikosyn, Pfizer’s branded product, no longer has meaningful market exclusivity. Current value is concentrated in generic supply, hospital access, manufacturing reliability, and regulatory compliance rather than patent protection.
What is dofetilide and how is it used?
Dofetilide is a Class III antiarrhythmic that blocks the cardiac rapid delayed rectifier potassium current. The FDA approved Tikosyn in 1999 for conversion to normal sinus rhythm and maintenance of sinus rhythm in patients with atrial fibrillation or atrial flutter.[1]
The drug is supplied as oral capsules in three strengths:
| Strength |
Typical role |
| 125 mcg |
Reduced-dose treatment, often based on renal function or QT response |
| 250 mcg |
Intermediate dose |
| 500 mcg |
Standard maximum dose for eligible patients |
Dofetilide dosing depends on creatinine clearance. Initiation or reinitiation requires hospitalization for at least three days, continuous ECG monitoring, and access to cardiac resuscitation equipment because excessive QT prolongation can cause torsades de pointes, a potentially fatal ventricular arrhythmia.[1]
This inpatient requirement limits use relative to outpatient antiarrhythmic therapies such as amiodarone, dronedarone, flecainide, and sotalol. It also creates recurring demand from hospitals and electrophysiology practices for patients who require rhythm-control therapy but are unsuitable for alternatives.
What is the FDA regulatory status of dofetilide?
Dofetilide is FDA-approved and available as both the branded product Tikosyn and generic capsules. The primary regulatory risk is clinical management of QT prolongation rather than an unresolved approval issue.
The FDA labeling requires:
- Hospital initiation and monitoring.
- Baseline QT assessment.
- Renal-function-based dosing.
- Contraindication with several interacting medicines.
- Discontinuation if QT prolongation exceeds specified limits.
- Avoidance in patients with certain renal, electrolyte, or cardiac-risk profiles.
The product is not a biologic and does not face biosimilar competition. Generic manufacturers use the abbreviated new drug application pathway and demonstrate pharmaceutical equivalence and bioequivalence rather than repeating the full clinical development program.[2]
Dofetilide is not dependent on a complex delivery device, injectable presentation, or specialty manufacturing platform. Its manufacturing barriers are mainly active pharmaceutical ingredient quality, low-dose content uniformity, dissolution performance, and compliance with current good manufacturing practices.
What patents protect dofetilide and Tikosyn?
Dofetilide’s principal US composition and product exclusivity periods have expired. The commercial market is therefore governed primarily by generic competition rather than by an enforceable blocking patent estate.
| Protection category |
Commercial position |
| Active-ingredient protection |
Expired |
| Original Tikosyn product protection |
Expired |
| Pediatric exclusivity |
Not a current commercial barrier |
| Formulation patents |
No material blocking formulation estate is generally recognized for current US supply |
| Method-of-use patents |
No broad, commercially blocking method-of-use protection is generally recognized |
| Orange Book leverage |
Limited or absent for current generic entry |
The Orange Book identifies approved drug products, therapeutic equivalence evaluations, and listed patents or exclusivities where applicable.[3] Tikosyn’s historical patent protection no longer prevents generic approval or launch. Any patent analysis for a new formulation, controlled-release product, combination product, or new indication would need to be conducted separately from the legacy immediate-release capsule estate.
How many patents cover dofetilide?
No active, broad US patent estate is known to provide meaningful exclusivity for the established immediate-release dofetilide capsule market. Historical patents may remain visible in legacy prosecution or product records, but expiration eliminates their ability to block ordinary generic capsules.
Patent risk could re-emerge only through a new product configuration, such as:
- A modified-release oral formulation.
- A fixed-dose combination.
- A new dosing method supported by clinical evidence.
- A hospital administration or monitoring technology linked to a separately patented product.
- A manufacturing process that produces a legally enforceable and commercially important advantage.
Those approaches would require new patent filings and would not restore exclusivity to the existing capsule product automatically.
When does dofetilide lose exclusivity?
Dofetilide lost effective US market exclusivity before the 2020s. FDA records show generic dofetilide approvals beginning in 2011, ending the practical monopoly of Tikosyn capsules.[4]
The exclusivity timeline is:
| Event |
Timing |
| FDA approval of Tikosyn |
1999 |
| Original branded commercial period |
1999 to early 2010s |
| Generic dofetilide approvals |
Beginning in 2011 |
| Current status |
Mature multi-source generic market |
| Future loss of exclusivity event |
None material for the legacy product |
The relevant commercial date is generic entry, not only the formal expiration date of a historical patent. Once multiple manufacturers entered, price competition became the dominant market force.
Which companies manufacture or challenge dofetilide?
Generic dofetilide has been marketed or approved by several manufacturers over time, including companies such as Mylan, Teva, Sun Pharmaceutical, Zydus, and other ANDA holders. The active supplier set can change because of product discontinuations, manufacturing transfers, shortages, and portfolio rationalization.[4]
Pfizer remains associated with Tikosyn, but the economic position of the branded product is materially weaker than during the exclusivity period. Generic manufacturers compete on:
- Wholesale acquisition cost.
- Distributor and group-purchasing contracts.
- Reliable supply of all three capsule strengths.
- Ability to maintain FDA-compliant production.
- Hospital formulary access.
- Pharmacy benefit coverage.
- Continuity during shortage events.
Are there Paragraph IV challenges to dofetilide?
Paragraph IV litigation was relevant when generic applicants challenged unexpired listed patents. It is not the principal current risk for dofetilide because the core product is already exposed to generic competition and has no widely recognized blocking patent barrier.
Generic applicants may still make patent certifications during ANDA review, but those filings do not necessarily produce meaningful commercial litigation. The absence of a blocking patent estate reduces the value of Paragraph IV exclusivity as a strategic asset.
No material current Paragraph IV dispute is central to the commercial outlook for standard dofetilide capsules based on the public FDA and product-record landscape.[3][4]
What is the Orange Book status of Tikosyn?
The Orange Book remains the key source for evaluating listed patents, therapeutic equivalence codes, and reference-listed-drug status. Tikosyn is the reference product for generic dofetilide capsules.
Its economic relevance is limited because:
- Generic versions have been approved.
- Immediate-release capsule technology is established.
- The core indication is covered by the original label.
- No active formulation or method-of-use patent is widely viewed as blocking generic entry.
- The product does not rely on a device or biologic interchangeability framework.
A company evaluating entry should still confirm the current Orange Book record, FDA discontinuation status, any newly listed patent, and the precise reference-listed-drug relationship before filing or acquiring an ANDA.
How strong is the dofetilide patent estate?
The patent estate is weak for the legacy product and potentially stronger only for future reformulations.
| Patent factor |
Assessment |
| Core molecule |
Weak commercial protection because historical protection expired |
| Immediate-release capsule |
Weak; established generic technology |
| Clinical indication |
Weak as a blocking position for the approved use |
| Manufacturing process |
Potentially relevant but unlikely to block all suppliers |
| New formulation |
Potentially protectable |
| New combination |
Potentially protectable |
| Regulatory exclusivity |
Not a current source of meaningful protection |
| Litigation leverage |
Low for standard capsules |
A process patent could create a manufacturing dispute without preventing competitors from using alternative processes. Formulation patents would have greater value only if the new formulation delivered a clinically meaningful benefit and captured reimbursement or prescriber demand.
What formulations are protected by dofetilide patents?
The commercially established product is an immediate-release hard capsule. There is no widely recognized, commercially dominant extended-release dofetilide formulation with separate market exclusivity.
The main technical opportunities for new intellectual property would involve:
- Modified-release delivery.
- Reduced peak plasma concentration.
- Improved dose flexibility.
- Renal-function-adjusted dosing.
- Lower monitoring burden.
- Fixed-dose combinations with complementary cardiovascular drugs.
- Safer initiation protocols supported by a new formulation or monitoring system.
These concepts would face a high clinical and regulatory bar. Any product that retains the risk of QT prolongation would still require robust cardiac safety evidence. A new formulation would not necessarily eliminate the inpatient initiation requirement without FDA-approved labeling changes supported by clinical data.
What patent litigation affects dofetilide?
No major active US patent litigation is generally associated with the established dofetilide capsule market. The principal legal risks are commercial and regulatory rather than patent-driven.
Potential disputes could involve:
- ANDA approval timing.
- Manufacturing quality.
- Drug shortage allocation.
- Product liability related to torsades de pointes.
- Labeling adequacy.
- Distribution contracts.
- False or misleading promotional claims.
- Patent enforcement for a newly developed formulation.
The product’s safety profile creates greater exposure to pharmacovigilance and product-liability issues than to legacy patent litigation. FDA labeling specifically warns about ventricular arrhythmia risk and the need for controlled initiation.[1]
What generic entry risks exist for dofetilide?
Generic entry is already established. The current risk is not initial entry but continued supplier expansion, price erosion, and possible supply consolidation.
The market has several structural risks:
Price erosion
Dofetilide capsules are a mature generic product. Additional ANDA holders can reduce net prices, especially for high-volume strengths such as 500 mcg. Pharmacy benefit managers, wholesalers, hospitals, and group-purchasing organizations can intensify price competition.
Supplier concentration
The product is inexpensive but clinically important for a defined patient population. If manufacturers discontinue low-margin strengths, temporary shortages can occur. A shortage can improve pricing for remaining suppliers but increases regulatory and operational scrutiny.
Dose-specific supply gaps
All three strengths are needed because dosing depends on renal function and QT response. A manufacturer that supplies only one or two strengths may have limited formulary value.
Hospital initiation constraints
The drug’s inpatient initiation requirement limits demand growth. It also reduces the value of consumer marketing and makes market access dependent on cardiology, electrophysiology, hospital pharmacy, and formulary decisions.
Substitution pressure
Clinicians may choose amiodarone, sotalol, catheter ablation, or other rhythm-control approaches. Dofetilide remains relevant where its efficacy and clinical profile justify monitored initiation, but its market is not expanding rapidly.
How does dofetilide compare with competing antiarrhythmics?
| Drug |
Main commercial advantage |
Main limitation |
| Dofetilide |
Effective rhythm-control option with no major extracardiac toxicity signal comparable to amiodarone |
Mandatory inpatient initiation and torsades risk |
| Amiodarone |
Broad efficacy and established use |
Pulmonary, thyroid, hepatic, ocular, and other long-term toxicities |
| Sotalol |
Familiar Class III and beta-blocking activity |
QT risk, renal dosing, and initiation monitoring |
| Dronedarone |
Outpatient-oriented branded positioning in selected patients |
Lower efficacy and important contraindications |
| Flecainide |
Effective in selected patients with structurally normal hearts |
Not suitable for many patients with structural heart disease |
| Catheter ablation |
Nonpharmacologic rhythm-control option |
Procedural cost, capacity, and patient-selection constraints |
Dofetilide’s competitive position is strongest when clinicians want a rhythm-control drug for patients who are poor candidates for long-term amiodarone or other agents. Its position is weaker when hospitalization, monitoring capacity, or procedural treatment is preferred.
What is the financial trajectory of dofetilide?
Pfizer does not report Tikosyn revenue as a separate material line item in its public financial disclosures. That prevents a reliable standalone revenue series from company filings.[5]
The financial trajectory is nevertheless clear:
| Period |
Financial profile |
| 1999 to early 2010s |
Branded, patent-supported product with higher pricing power |
| From 2011 generic entry |
Revenue and price pressure increased |
| Mature generic period |
Lower net prices, fragmented supply, limited brand leverage |
| Current outlook |
Stable niche demand with modest growth and low probability of major revenue expansion |
For Pfizer, dofetilide is unlikely to be a material driver of group revenue. The branded product’s value is constrained by generic substitution and the absence of meaningful exclusivity. For generic manufacturers, the product can generate recurring revenue but is unlikely to become a major growth asset unless a company secures a differentiated formulation, a shortage-related supply advantage, or a broader hospital contract.
What is the revenue exposure from dofetilide?
Revenue exposure is asymmetric:
- Pfizer has limited branded upside.
- Generic manufacturers face low unit prices but recurring demand.
- Distributors benefit from predictable prescription volume rather than high gross margins.
- Hospitals incur initiation-monitoring costs that can exceed the drug acquisition cost.
- A new entrant could gain share through supply reliability rather than superior clinical differentiation.
The product’s economic value is therefore tied to prescription continuity and manufacturing execution. It is not a high-growth branded cardiovascular asset.
Are there licensing deals for dofetilide?
No major current licensing transaction is publicly associated with the standard generic dofetilide capsule market. Pfizer’s historical ownership and commercialization of Tikosyn are more relevant than any active licensing arrangement.
A licensing opportunity would be more plausible for:
- A modified-release formulation.
- A combination product.
- A diagnostic or ECG-monitoring platform.
- A new initiation protocol.
- A manufacturing technology that improves yield or dose uniformity.
A license limited to legacy immediate-release capsules would have weak bargaining value unless it included protected supply, an established hospital contract, or a defensible manufacturing advantage.
What generic launch scenarios remain?
There are three practical scenarios for future entrants.
Base case
A new ANDA enters an already competitive market. Pricing declines gradually, and market share depends on wholesaler contracts, pharmacy coverage, and supply reliability.
Upside case
A manufacturer gains share because one or more competitors experience a shortage, manufacturing warning letter, voluntary recall, or discontinuation. The benefit is usually temporary unless the entrant establishes dependable multi-strength supply.
Differentiation case
A company develops a new formulation or clinical-use model that receives separate patent and regulatory protection. This is the only scenario capable of creating durable pricing power, but it requires new clinical evidence and a market large enough to justify development costs.
What manufacturing and intellectual-property barriers affect the market?
The active ingredient is a small molecule, so dofetilide does not have the biologic manufacturing complexity associated with monoclonal antibodies or cell therapies. The key barriers are operational:
- Consistent low-dose capsule filling.
- Control of impurities.
- Batch-to-batch content uniformity.
- Dissolution and stability.
- Qualified API sourcing.
- Validation of analytical methods.
- Compliance with FDA inspection requirements.
- Maintenance of all dose strengths.
- Capacity to respond to hospital and wholesaler orders.
Manufacturing IP may provide a cost advantage, but it is unlikely to block market entry unless competitors cannot readily design around the process. Regulatory compliance and supply continuity are more important than legacy patent ownership.
Key Takeaways
- Dofetilide is an FDA-approved Class III antiarrhythmic marketed as Tikosyn and generic capsules.
- Generic entry began in 2011, ending meaningful branded exclusivity.
- The immediate-release capsule market has weak patent protection and limited current litigation exposure.
- No biosimilar issue applies because dofetilide is a small-molecule drug.
- Demand is stable but constrained by mandatory inpatient initiation and QT-monitoring requirements.
- Pfizer does not separately disclose Tikosyn revenue, and the product is unlikely to be a material contributor to Pfizer’s financial results.
- Generic value depends on multi-strength supply, manufacturing compliance, hospital access, and shortage resilience.
- Durable pricing power would require a new formulation, combination, or clinically differentiated delivery system.
FAQs
Is dofetilide still under patent protection?
The core dofetilide molecule and established immediate-release capsule product are no longer protected by meaningful blocking exclusivity in the US. Any newly patented formulation would need separate analysis.
Can a generic manufacturer launch dofetilide without Paragraph IV litigation?
Yes. Generic entry is already established, and a new applicant may proceed through the applicable ANDA certification pathway without creating a material patent dispute if no blocking listed patent applies.
Does dofetilide have biosimilar competition?
No. Dofetilide is a synthetic small molecule. Competition occurs through generic ANDAs, not biosimilar applications.
Why is dofetilide initiated in the hospital?
The drug can prolong the QT interval and cause torsades de pointes. FDA labeling requires monitored initiation so clinicians can adjust or stop treatment based on ECG and renal-function findings.
Could a new dofetilide formulation become commercially valuable?
Yes, but only if it provides a clinically meaningful benefit, receives FDA approval, and obtains enforceable patent or regulatory protection. A modified-release or safer-initiation product would face substantial clinical-development and cardiac-safety requirements.
References
-
U.S. Food and Drug Administration. (2023). Tikosyn (dofetilide) prescribing information. Pfizer Laboratories.
-
U.S. Food and Drug Administration. (2024). Generic drug facts and abbreviated new drug application requirements. https://www.fda.gov/drugs
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
Pfizer Inc. (2024). Annual report for the fiscal year ended December 31, 2023. https://www.pfizer.com/investors/financials/annual-reports
